Page last updated: 2024-11-07

penta-o-ethylquercetin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

penta-O-ethylquercetin: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID133942
CHEMBL ID18487
MeSH IDM0160756

Synonyms (9)

Synonym
4h-1-benzopyran-4-one, 2-(3,4-diethoxyphenyl)-3,5,7-triethoxy-
penta-o-ethylquercetin
82547-07-7
CHEMBL18487 ,
2-(3,4-diethoxyphenyl)-3,5,7-triethoxychromen-4-one
bdbm50404742
3,5,7,3',4'-pentaethoxyflavone
DTXSID701002773
2-(3,4-diethoxyphenyl)-3,5,7-triethoxy-4h-1-benzopyran-4-one
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BRattus norvegicus (Norway rat)IC50 (µMol)1,000.00000.10000.20000.3000AID220159
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CRattus norvegicus (Norway rat)IC50 (µMol)1,000.00000.10000.20000.3000AID220159
Phosphodiesterase Rattus norvegicus (Norway rat)IC50 (µMol)1,000.00000.10000.20000.3000AID220159
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID219998Inhibition of rat brain cytosolic cAMP phosphodiesterase1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Pentasubstituted quercetin analogues as selective inhibitors of particulate 3':5'-cyclic-AMP phosphodiesterase from rat brain.
AID220006Relative inhibition of cAMP and cGMP hydrolysis by particulate phosphodiesterase1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Pentasubstituted quercetin analogues as selective inhibitors of particulate 3':5'-cyclic-AMP phosphodiesterase from rat brain.
AID220001Inhibition of rat brain cytosolic cAMP phosphodiesterase1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Pentasubstituted quercetin analogues as selective inhibitors of particulate 3':5'-cyclic-AMP phosphodiesterase from rat brain.
AID220005Relative inhibition of cAMP and cGMP hydrolysis by cytosolic phosphodiesterase1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Pentasubstituted quercetin analogues as selective inhibitors of particulate 3':5'-cyclic-AMP phosphodiesterase from rat brain.
AID220159Inhibition of rat brain cytosolic cGMP phosphodiesterase1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Pentasubstituted quercetin analogues as selective inhibitors of particulate 3':5'-cyclic-AMP phosphodiesterase from rat brain.
AID220162Inhibition of rat brain particulate cGMP phosphodiesterase1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Pentasubstituted quercetin analogues as selective inhibitors of particulate 3':5'-cyclic-AMP phosphodiesterase from rat brain.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (75.00)18.7374
1990's1 (25.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.53 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]